The study, conducted by Hazal Ozdemir Koyu of Selcuk University and Cigdem Sari Öztürk of Gazi University in Turkey, addressed a persistent gap in survivorship care. Thanks to dramatic advances in pediatric oncology, the vast majority of children diagnosed with cancer now survive into adulthood. Yet survival comes at a cost: research consistently shows that adolescent and young adult (AYA) survivors face elevated risks of anxiety, depression, cancer-related worry, fear of recurrence, and diminished quality of life compared with their healthy peers. Many also struggle with the transition from pediatric to adult follow-up care, often dropping out of surveillance entirely during the very years when psychosocial support is most needed.

To evaluate whether digital tools could help, the researchers searched seven major databases—PubMed, CINAHL, the Cochrane Library, PsycINFO, Embase, Scopus, and Web of Science—for randomized controlled trials published between 2015 and 2025. Randomized designs are considered the gold standard for establishing causality because they assign participants by chance to either an intervention or a control condition, minimizing the influence of confounding factors. The team registered its protocol in advance with PROSPERO, the international prospective register of systematic reviews, and followed the PRISMA 2020 reporting guidelines, both steps that strengthen the credibility and transparency of meta-analytic work.

The final analysis pooled data from ten randomized controlled trials encompassing 747 participants. The interventions varied considerably in format and content, reflecting the breadth of the digital health landscape. Included studies featured mobile instant messaging programs delivering brief motivational interviewing, a chatbot named Vivibot that taught positive psychology skills, online group-based psychological support through the Recapture Life trial, web-based resources for improving cancer knowledge, online cognitive behavioral therapy for insomnia, internet-based behavioral activation for brain tumor survivors, and digital coach-assisted programs designed to enhance hope. Outcomes of interest were quality of life, anxiety, depression, psychological distress, and emotional well-being.

Methodologically, the authors assessed the risk of bias in each trial using the revised Cochrane RoB 2 tool, which evaluates potential flaws in randomization, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting. They then pooled standardized mean differences (SMDs) with 95 percent confidence intervals using random-effects models in RevMan Web. Standardized mean differences express the size of an effect in units of pooled standard deviation, allowing results measured on different scales to be combined; by convention, values around 0.2 are considered small, 0.5 moderate, and 0.8 large. The random-effects approach assumes that true effects may vary across studies, which is appropriate given the heterogeneity of the interventions examined. The team also quantified heterogeneity using the I-squared statistic, performed subgroup analyses by assessment timing, and conducted leave-one-out sensitivity analyses to test whether any single trial was driving the pooled results.

The headline finding was a small but statistically significant improvement in overall quality of life, with an SMD of 0.24 (95 percent confidence interval 0.09 to 0.39, p = 0.001). Intriguingly, the timing of assessment mattered enormously. Immediately after the interventions ended, the effect on quality of life was not statistically significant. But at follow-up assessments conducted six to twenty-four months later, the effect grew to a small-to-moderate SMD of 0.36 (95 percent confidence interval 0.11 to 0.60, p = 0.004). This pattern suggests that the skills and insights these digital programs impart—coping strategies, resilience techniques, health self-management—may take time to translate into measurable improvements in how survivors experience their lives, and that their benefits endure well beyond the active intervention period.

The anxiety results were similarly encouraging. The analysis revealed a small-to-moderate reduction in anxiety, with an SMD of −0.35 (95 percent confidence interval −0.65 to −0.05, p = 0.02). For a population in which fear of cancer recurrence and persistent health-related worry are among the most commonly reported burdens, even a modest reduction in anxiety could have meaningful clinical implications. Anxiety in survivors is not merely an emotional inconvenience; it is associated with avoidance of medical follow-up, poorer adherence to surveillance recommendations, and degraded day-to-day functioning, so interventions that reliably move this needle deserve serious attention from clinicians designing survivorship programs.

Not every outcome showed a clear benefit. Effects on depression (SMD = −0.31), psychological distress (SMD = −0.04), and emotional well-being (SMD = 0.20) did not reach statistical significance. The authors attribute this variability partly to the modest number of trials and the diversity of outcome measures used across studies, which complicates pooling and can obscure real effects. The near-zero result for distress, in particular, may reflect the heterogeneity of instruments used to capture it, or the possibility that generic distress is less responsive to brief digital interventions than specific symptoms like anxiety. The finding underscores a recurring theme in digital health research: promising signals in one domain do not automatically generalize across the full spectrum of psychological outcomes.

The study’s strengths lie in its rigorous adherence to established meta-analytic standards—pre-registration, PRISMA-compliant reporting, formal risk-of-bias assessment, and sensitivity analyses—while its limitations mirror those of the underlying evidence base. Ten trials and 747 participants is a small foundation on which to build definitive clinical recommendations, and the included interventions differed widely in dose, delivery platform, theoretical grounding, and target outcomes. The authors are candid about this, calling for larger, theory-driven randomized trials with standardized outcome measures to clarify which digital approaches work best, for whom, and under what conditions. Such precision would allow clinicians to match survivors to the interventions most likely to help them, rather than offering a one-size-fits-all digital program.

Nevertheless, the implications are significant for a generation that lives online. AYA survivors are digital natives, and technology-delivered care sidesteps many practical barriers that make traditional psychosocial services hard to reach: geographic distance from specialized cancer centers, inflexible scheduling around school and work, and the simple reluctance of young people to seek in-person mental health care. The evidence that benefits may strengthen rather than decay over months is particularly noteworthy, hinting that digital interventions could serve as durable scaffolding during the precarious transition to adult survivorship care. As the authors conclude, technology-based psychosocial interventions offer modest but statistically significant gains in quality of life and anxiety relief for young survivors of childhood cancer—and with better-designed trials on the horizon, the digital toolkit for this population may be only beginning to show what it can do.

Subject of Research: Technology-based psychosocial interventions for improving quality of life and psychological outcomes in adolescent and young adult survivors of childhood cancer

Article Title: Efficacy of technology-based psychosocial interventions on quality of life and psychological outcomes in adolescent and young adult survivors of childhood cancer: a systematic review and meta-analysis of randomized controlled trials

Article References: Koyu, H. O., & Öztürk, C. S. (2026). Efficacy of technology-based psychosocial interventions on quality of life and psychological outcomes in adolescent and young adult survivors of childhood cancer: a systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer, 34(10), Article 1072. https://doi.org/10.1007/s00520-026-11280-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11280-y

Keywords: childhood cancer, cancer survivors, adolescent and young adult, digital health, psychosocial interventions, quality of life, anxiety, meta-analysis, randomized controlled trials, survivorship care, mental health, telehealth